Rhythm Pharmaceuticals

RYTM

Market cap $6.38B

Overview Fund Activity

96.10 USD

+0.58

0.61%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

96.00

-0.10

0.1%

1 day

0.61%

5 days

-4.01%

1 month

-2.03%

3 months

55.08%

6 months

83.61%

Year to date

59.98%

1 year

80.74%

5 years

237.67%

10 years

220.33%

About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Employees: 283

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

43% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 10 (+3) [Q2]

24% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 74

23% more capital invested

Capital invested by funds: $3.42B [Q1] → $4.2B (+$780M) [Q2]

2.42% more ownership

Funds ownership: 102.18% [Q1] → 104.59% (+2.42%) [Q2]

3% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 33

0% more funds holding

Funds holding: 227 [Q1] → 227 (+0) [Q2]

62% less call options, than puts

Call options by funds: $13.8M | Put options by funds: $36.7M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$95

1% downside

Avg. target

$110

14% upside

High target

$135

40% upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	$100	Buy Maintained	7 Aug 2025
Morgan Stanley Jeffrey Hung	$109	Overweight Maintained	6 Aug 2025
JMP Securities Jonathan Wolleben	$135	Market Outperform Maintained	6 Aug 2025
Guggenheim Seamus Fernandez	$120	Buy Maintained	6 Aug 2025
Canaccord Genuity Whitney Ijem	$105	Buy Maintained	18 Jul 2025
Leerink Partners Faisal Khurshid	$102	Outperform Maintained	10 Jul 2025
Oppenheimer Leland Gershell	$110	Outperform Maintained	10 Jul 2025
B of A Securities Tazeen Ahmad	$95	Buy Maintained	10 Jul 2025
Wells Fargo Derek Archila	$129	Overweight Maintained	10 Jul 2025
Needham Joseph Stringer	$95	Buy Maintained	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about RYTM published over the past 30 days

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants David Meeker - Chairman, President & CEO Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

Rhythm Pharmaceuticals, Inc. (RYTM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity –

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

The Motley Fool

Rhythm (RYTM) Q2 Revenue Jumps 67%

Rhythm Pharmaceuticals (RYTM -1.85%), a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ($0.75).

Rhythm (RYTM) Q2 Revenue Jumps 67%

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David P. Meeker - Chairman, President & CEO Hunter C.

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

-- Second quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $48.5 million -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Bivamelagon Phase 2 trial met primary endpoint with statistically significant, clinically meaningful BMI reductions in patients with acquired hypothalamic obesity -- -- Raised approximately $189.2 million in net proceeds in upsized public offering of common stock -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the second quarter ended June 30, 2025.

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Zacks Investment Research

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 5, 2025 to report its second quarter 2025 financial results and provide a corporate update.

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

The Motley Fool

Should You Invest in This Under-the-Radar Weight Loss Stock?

If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two are the undisputed leaders in the field.

Should You Invest in This Under-the-Radar Weight Loss Stock?

See News Rankings

Charts implemented using Lightweight Charts™